- Conditions
- Prostate Cancer, Prostate, Prostate Adenocarcinoma
- Interventions
- 68Gallium-PSMA-11, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 189
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration
- Procedure · Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Interventions
- 68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Prostate Cancer
- Interventions
- 225Ac-J591
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Brooklyn, New York • New York, New York
- Conditions
- Prostate Cancer, Prostate Neoplasm
- Interventions
- 18F-DCFPyL PET
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Biochemically Recurrent Prostate Cancer
- Interventions
- Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- CTT1057
- Drug
- Lead sponsor
- Cancer Targeted Technology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hyperparathyroidism
- Interventions
- 99mTc-MIBI planar imaging and SPECT/CT., F- 18PSMA PET/CT imaging study
- Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Johns Creek, Georgia
- Conditions
- Renal Cell Carcinoma
- Interventions
- PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma
- Interventions
- Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Angiogram, Catheterization, Gallium Ga-labeled PSMA-11, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Ryan Kohlbrenner, MD
- Other
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer
- Interventions
- Ga-68 labeled PSMA-11 PET
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Ga-68 labeled PSMA-11 PET
- Drug
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer
- Interventions
- PSMA-guided Salvage Radiation
- Radiation
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 30 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Prostate Cancer
- Interventions
- 18F-rhPSMA-7.3
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Surgical Procedure
- Procedure · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 133
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasm of Uncertain Behavior
- Interventions
- Ga-68 PSMA-HBED-CC PET
- Drug
- Lead sponsor
- Michael Graham PhD, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Flotufolastat F-18, Lutetium Lu 177 PSMA-10.1, Positron Emission Tomography, Single Photon Emission Computed Tomography
- Procedure · Radiation · Other + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer, Prostate Neoplasms
- Interventions
- 18F-NaF, 18F-DCFPyL, 18F-FDG
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- (64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, PET/MRI/fluorescence imaging, Blood and urine sampling, laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection, 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots
- Drug · Diagnostic Test · Other + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel
- Drug
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 9
- States / cities
- Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more
- Conditions
- Prostate Cancer
- Interventions
- 89ZR-DF-IAB2M, 68Ga-PSMA-HBED-CC
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Interventions
- Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
- Drug · Device · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri